Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell Receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    716 result(s) found for: Cell Receptor. Displaying page 1 of 36.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-004557-24 Sponsor Protocol Number: UKM17_0056 Start Date*: 2019-07-29
    Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2010-023869-21 Sponsor Protocol Number: ML25575 Start Date*: 2011-02-09
    Sponsor Name:Roche Oy
    Full Title: A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal ...
    Medical condition: Locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018614-70 Sponsor Protocol Number: D791AC00014 Start Date*: 2010-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Gr...
    Medical condition: Non Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025053 Lung cancer non-small cell stage IIIA LLT
    12.1 10025054 Lung cancer non-small cell stage IIIB LLT
    12.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) NO (Completed) HU (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-001673-14 Sponsor Protocol Number: CCTL019A2205B Start Date*: 2015-10-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
    Medical condition: All patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FI (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005460-28 Sponsor Protocol Number: CRAD001L2401 Start Date*: 2008-07-18
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor...
    Medical condition: Pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor del factor de crecimiento endotelial vascular
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) AT (Completed) SK (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Completed) GB (Completed) BE (Completed) GR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000966-40 Sponsor Protocol Number: EC-FV-07 Start Date*: 2012-07-04
    Sponsor Name:Endocyte, Inc.
    Full Title: A Randomized, Open-Label Phase 2 Study of EC145 Single-agent and the Combination of EC145 plus Docetaxel Versus Docetaxel Alone in Participants with Folate-Receptor Positive [FR(++)] Second Line NSCLC
    Medical condition: Second line FR(++) non-small cell lung cancer (adenocarcinoma, squamous, adenosquamous, or adenocarcinoma with other NSCLC variants of the lung) (Stage IIIB or IV).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) GB (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003667-11 Sponsor Protocol Number: M15-550 Start Date*: 2016-08-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE I)
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) SE (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) IE (Completed) PT (Completed) FI (Completed) DK (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003192-11 Sponsor Protocol Number: ANZGOG0903 Start Date*: 2012-09-07
    Sponsor Name:University of Sydney [...]
    1. University of Sydney
    2. University of Sydney
    Full Title: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
    Medical condition: Women with oestrogen receptor and/or progesterone receptor positive (ER/PR+ve) potentially hormone responsive recurrent or metastatic gynaecological cancer including selected patients with epitheli...
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005371-16 Sponsor Protocol Number: D4302C00001 Start Date*: 2012-07-30
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Medical condition: Diffuse Large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002485-19 Sponsor Protocol Number: 08061 Start Date*: 2008-11-21
    Sponsor Name:EORTC-European Organisation for Research and Treatment of Cancer
    Full Title: Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a "sensitive" relapse
    Medical condition: Patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse (extensive or limited disease).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002168-26 Sponsor Protocol Number: ML27880 Start Date*: 2012-01-05
    Sponsor Name:Roche (Magyarország) Kft.
    Full Title: OPEN LABEL STUDY OF ERLOTINIB (TARCEVA®) AS SINGLE AGENT FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (E...
    Medical condition: Open label study of erlotinib (Tarceva®) as single agent first line treatment of patients with locally advanced or metastatic lung adenocarcinoma with activating Epidermal Growth Factor Receptor (E...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2012-000155-14 Sponsor Protocol Number: V2.0 Start Date*: 2013-12-13
    Sponsor Name:Med. Universität Wien, Universitätsklinik für Innere Medizin II
    Full Title: In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD
    Medical condition: COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001058-16 Sponsor Protocol Number: NLG-LBC-07 Start Date*: 2017-02-15
    Sponsor Name:Nordic Lymphoma Group
    Full Title: A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma.
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma, including transformed low grade lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003361-18 Sponsor Protocol Number: PM0259CA229J1 Start Date*: 2013-01-24
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after a failure to tr...
    Medical condition: Patients with: -Histologically or cytologically confirmed NSCLC (stage IIIB or IV) and -epidermal growth factor receptor (EGFR) positive mutation and -previously treated with tyrosine kinase inhibi...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000307-10 Sponsor Protocol Number: TREM Start Date*: 2015-05-27
    Sponsor Name:Oslo university hospital
    Full Title: AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.
    Medical condition: Locally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) DK (Completed) FI (Ongoing) LT (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000781-23 Sponsor Protocol Number: GEN207 Start Date*: 2008-06-09
    Sponsor Name:Genmab A/S
    Full Title: An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination wi...
    Medical condition: Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023860 Laryngeal squamous cell carcinoma stage III LLT
    9.1 10023861 Laryngeal squamous cell carcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001642-28 Sponsor Protocol Number: INCB39110-205 Start Date*: 2015-09-28
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer Whose Tu...
    Medical condition: Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, e...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003568-73 Sponsor Protocol Number: GECP06/01 Start Date*: 2008-05-07
    Sponsor Name:Grupo Espagnol de Cancer de Pulmon
    Full Title: Phase III, Multicenter, Open-label, Randomized Study of Erlotinib (Tarceva®) Treatment Versus Chemotherapy in Patients with Advanced Non-small-cell Carcinoma of the Lung Who Present Mutations in th...
    Medical condition: Non-squamous-cell, non-small-cell lung cancer in stage IIIB and IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000104-42 Sponsor Protocol Number: U31287-A-U201E Start Date*: 2013-06-14
    Sponsor Name:DAIICHI SANKYO DEVELOPMENT LTD.
    Full Title: Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension
    Medical condition: Treatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019660-36 Sponsor Protocol Number: Anakinra1 Start Date*: 2010-12-07
    Sponsor Name:UMC St Radboud
    Full Title: The effect of interleukin-1 receptor antagonist on insulin secretion
    Medical condition: Beta-cell dysfunction
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052341 Impaired insulin secretion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:41:44 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA